The potential of progestin modulators as anti-tumor agents has recently been addressed using a patient derived xenograft model of breast cancer; investigators showed ulipristal acetate, a selective progesterone receptor modulator translated to significant anti-tumor effect, with reduction in Ki67 and Cyclin D1 [88]. This evidence concerns the gene PGR and breast cancer.